Glioblastoma
CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts
CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position
Actionable Insights Powered by AI
CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position